We Think Curasight (NGM:CURAS) Has A Fair Chunk Of Debt
May 20
Have your own idea? Try our Stock Screener
Swedish (OMX) Biotech Industry Analysis
UpdatedMay 21, 2025
DataAggregated Company Financials
Companies60
- 7D2.1%
- 3M-9.7%
- 1Y-2.1%
- YTD-12.0%
The Biotech industry is up 1.4% in the last week, with Swedish Orphan Biovitrum up 3.0%. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 28% per annum.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 21 May 2025 | SEK 193.6b | SEK 33.9b | SEK 1.2b | 34.5x | 161.1x | 5.7x |
| Fri, 18 Apr 2025 | SEK 175.2b | SEK 33.7b | SEK 758.3m | 29x | 231.1x | 5.2x |
| Sun, 16 Mar 2025 | SEK 196.7b | SEK 33.7b | SEK 579.2m | 33.2x | 339.6x | 5.8x |
| Tue, 11 Feb 2025 | SEK 218.0b | SEK 33.7b | SEK 360.5m | 54.6x | 604.8x | 6.5x |
| Thu, 09 Jan 2025 | SEK 219.4b | SEK 33.0b | -SEK 4,418,647,416.22 | 160.3x | -49.6x | 6.6x |
| Sat, 07 Dec 2024 | SEK 214.0b | SEK 33.0b | -SEK 4,445,855,070.07 | 146.4x | -48.1x | 6.5x |
| Mon, 04 Nov 2024 | SEK 215.9b | SEK 33.2b | -SEK 4,482,059,813.14 | 138.3x | -48.2x | 6.5x |
| Wed, 02 Oct 2024 | SEK 210.4b | SEK 31.4b | -SEK 5,523,741,940.78 | 49.5x | -38.1x | 6.7x |
| Fri, 30 Aug 2024 | SEK 212.8b | SEK 31.4b | -SEK 5,507,219,147.57 | 51x | -38.6x | 6.8x |
| Sun, 28 Jul 2024 | SEK 205.1b | SEK 31.4b | -SEK 5,422,714,425.02 | 46.9x | -37.8x | 6.5x |
| Tue, 25 Jun 2024 | SEK 195.4b | SEK 30.6b | -SEK 5,516,807,975.13 | 39.1x | -35.4x | 6.4x |
| Thu, 23 May 2024 | SEK 190.8b | SEK 30.6b | -SEK 5,462,243,356.40 | 39.4x | -34.9x | 6.2x |
| Sat, 20 Apr 2024 | SEK 177.7b | SEK 29.8b | -SEK 5,266,079,807.91 | 63.7x | -33.8x | 6x |
| Mon, 18 Mar 2024 | SEK 186.1b | SEK 29.8b | -SEK 5,636,600,511.99 | 59.6x | -33x | 6.2x |
| Wed, 14 Feb 2024 | SEK 173.7b | SEK 29.6b | -SEK 5,690,161,945.72 | 60.6x | -30.5x | 5.9x |
| Fri, 12 Jan 2024 | SEK 187.1b | SEK 28.7b | -SEK 1,198,694,522.00 | 58.8x | -156.1x | 6.5x |
| Sun, 10 Dec 2023 | SEK 169.9b | SEK 28.7b | -SEK 1,200,221,950.00 | 58.4x | -141.6x | 5.9x |
| Tue, 07 Nov 2023 | SEK 157.8b | SEK 28.6b | -SEK 1,293,138,519.00 | 48.4x | -122x | 5.5x |
| Thu, 05 Oct 2023 | SEK 161.2b | SEK 27.4b | -SEK 2,017,277,396.00 | 47.8x | -79.9x | 5.9x |
| Sat, 02 Sep 2023 | SEK 155.3b | SEK 27.4b | -SEK 1,967,118,727.00 | 52.5x | -78.9x | 5.7x |
| Mon, 31 Jul 2023 | SEK 156.0b | SEK 27.5b | -SEK 1,534,283,427.00 | 55.8x | -101.7x | 5.7x |
| Wed, 28 Jun 2023 | SEK 160.4b | SEK 26.4b | -SEK 1,312,987,475.00 | 45.5x | -122.2x | 6.1x |
| Fri, 26 May 2023 | SEK 171.9b | SEK 26.3b | -SEK 1,366,671,495.00 | 45.3x | -125.8x | 6.5x |
| Sun, 23 Apr 2023 | SEK 173.8b | SEK 25.5b | -SEK 2,076,198,392.00 | 39.7x | -83.7x | 6.8x |
| Tue, 21 Mar 2023 | SEK 164.2b | SEK 25.4b | -SEK 2,030,181,364.00 | 37.8x | -80.9x | 6.5x |
| Thu, 16 Feb 2023 | SEK 176.3b | SEK 25.3b | -SEK 1,664,056,988.00 | 27x | -106x | 7x |
| Sat, 14 Jan 2023 | SEK 173.3b | SEK 23.8b | -SEK 1,844,394,225.00 | 31.6x | -94x | 7.3x |
| Mon, 12 Dec 2022 | SEK 157.5b | SEK 23.8b | -SEK 1,826,624,890.00 | 32.1x | -86.2x | 6.6x |
| Wed, 09 Nov 2022 | SEK 151.9b | SEK 23.9b | -SEK 3,186,214,696.00 | 33x | -47.7x | 6.4x |
| Fri, 07 Oct 2022 | SEK 155.4b | SEK 22.9b | -SEK 3,331,692,568.00 | 32.1x | -46.6x | 6.8x |
| Sun, 04 Sep 2022 | SEK 161.0b | SEK 22.9b | -SEK 3,245,057,861.00 | 33.6x | -49.6x | 7x |
| Tue, 02 Aug 2022 | SEK 173.8b | SEK 22.7b | -SEK 3,478,859,664.00 | 35.8x | -50x | 7.7x |
| Thu, 30 Jun 2022 | SEK 152.3b | SEK 21.4b | -SEK 3,520,100,841.00 | 38.4x | -43.3x | 7.1x |
| Sat, 28 May 2022 | SEK 157.9b | SEK 21.4b | -SEK 3,493,623,798.00 | 44.3x | -45.2x | 7.4x |
Price to Earnings Ratio
-45.2x
Current Industry PE
- Investors are optimistic on the Swedish Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 161x which is higher than its 3-year average PE of -48.5x.
- The 3-year average PS ratio of 6.4x is higher than the industry's current PS ratio of 5.7x.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 17% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | 0.62% | |
| Healthcare | 1.10% | |
| Biotech | 2.11% | |
| Biotech | 2.11% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SOBI Swedish Orphan Biovitrum | SEK 310.40 | 3.0% +SEK 3.1b | 11.5% | PE26.9x | |
| BIOA B BioArctic | SEK 185.00 | 7.6% +SEK 1.2b | -17.0% | PS63.6x | |
| CRNO B Cereno Scientific | SEK 10.75 | 18.1% +SEK 464.8m | 183.6% | PS37.4x | |
| CURAS Curasight | DKK 5.40 | 157.1% +DKK 69.8m | -46.0% | PB45.6x | |
| SANION Saniona | SEK 8.39 | 5.9% +SEK 64.0m | 318.5% | PE6.1x |
